You are here

P&T July 2011

Features

Reality and Expectations
Regulatory Compliance
A History of REMS Requirements, a Review of the Data, And an Approach to Compliance in the Hospital
Perspective
Formulary Considerations

Newer-generation branded proton pump inhibitors (PPIs) have shown some advantages over generic PPIs in the treatment of gastroesophageal reflux disease. These differences are discussed along with ways of incorporating the newer PPIs into formularies.